{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"57.0","upperLimit":"NA","value":"209.0"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"87.0","upperLimit":"NA","value":"168.0"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"53.0","upperLimit":"NA","value":"107.5"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG003","lowerLimit":"15.0","upperLimit":"NA","value":"55.5"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"10.0","upperLimit":"NA","value":"185.0"},{"groupId":"OG005","lowerLimit":"56.0","upperLimit":"220.0","value":"66.0"},{"groupId":"OG006","lowerLimit":"34.0","upperLimit":"114.0","value":"52.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"8"}],"units":"Participants"}],"description":"Interval of time from the date of first study drug administration to the documented date of disease progression or death, whichever occurred first, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \\[FDG\\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)","dispersionType":"95% Confidence Interval","groups":[{"description":"VRx-3996: 10 mg twice daily (BID) valganciclovir: 900 mg BID","id":"OG000","title":"Phase 1b Dose Escalation Cohort 1"},{"description":"VRx-3996: 5 mg BID valganciclovir: 450 mg BID","id":"OG001","title":"Phase 1b Dose Escalation Cohort 2a"},{"description":"VRx-3996: 10 mg once daily (QD) valganciclovir: 450 mg BID","id":"OG002","title":"Phase 1b Dose Escalation Cohort 2b"},{"description":"VRx-3996: 10 mg QD valganciclovir: 900 mg QD","id":"OG003","title":"Phase 1b Dose Escalation Cohort 2c"},{"description":"VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD","id":"OG004","title":"Phase 1b Dose Escalation Cohort 3"},{"description":"VRx-3996 (RP2D: 20 mg QD on Days 1 to 4/week) and valganciclovir (RP2D: 900 mg QD)","id":"OG005","title":"Phase 2 Expansion - Capsule"},{"description":"VRx-3996 (RP2D: 20 mg QD on Days 1 to 4/week) and valganciclovir (RP2D: 900 mg QD)","id":"OG006","title":"Phase 2 Expansion - Tablet"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Analysis Set, defined as all patients with measurable/evaluable disease at screening who met all eligibility criteria and had at least one evaluable post-baseline efficacy tumor assessment. Valganciclovir dosage reductions were allowed for participants with renal impairment at study entry or during study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"days"}